What Penn Medicine does

Penn Medicine is the University of Pennsylvania Health System, a nonprofit academic medical center combining clinical care, biomedical research, and medical education. Founded in 1751 as the nation's first hospital (Pennsylvania Hospital) and in 1765 as the nation's first medical school (Perelman School of Medicine), it operates seven hospitals and hundreds of outpatient clinics across 27 counties in Pennsylvania and New Jersey, serving an estimated 2.5–3 million patients annually and 300,000+ cancer patients specifically. The enterprise employs nearly 49,000 faculty and staff and is anchored by 7,060+ faculty and research staff, 4,590+ trainees, and 90 National Academy of Medicine members, including Nobel laureates Drew Weissman and Katalin Kariko.

The organization runs a vertically integrated portfolio spanning primary care, specialty care, transplant services, and highly complex interventions such as CAR T cell therapy (first FDA-approved cellular therapy for cancer), Luxturna gene therapy (first FDA-approved gene therapy for inherited blindness), and Cytalux fluorescence-guided surgery. Technology assets include the Penn Medicine OnDemand 24/7 telehealth platform (expanded to 63 practices, 2.3M+ lifetime virtual visits), the AI-driven AInsights imaging platform, Chart Hero generative AI EHR tool, CRISP clinical-reasoning AI, and a specialty pharmacy with the homegrown RefillExpress system reducing specialty drug delivery from 14–21 days to three days.

Penn Medicine's revenue is generated primarily through patient care services reimbursed by insurance, Medicare, and Medicaid across its seven-hospital system, supplemented by over $969 million in annual research funding (NIH, foundations, industry), philanthropy from named foundations (Abramson, Basser, Lancaster General, Princeton, Doylestown), and specialty pharmacy operations. First-half FY2026 revenue was $6.76 billion (up ~12% year-over-year), with operating profit of $189 million (up 62% YoY). Strategic priorities include geographic expansion via the Doylestown Health acquisition (2025), a $500M+ cancer facility build-out, enterprise-wide AI deployment through the K Health partnership, and continued translational research commercialization via the Penn Center for Innovation (330+ startups supported, $1.2B+ in sponsored research since 2014).

Name

Penn Medicine

Legal name

The Trustees of the University of Pennsylvania

Website

https://pennmedicine.org

Company type

Private

Founded year

1751

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Penn Medicine is the University of Pennsylvania Health System, a nonprofit academic medical center operating seven hospitals and hundreds of outpatient clinics across Pennsylvania and New Jersey. It delivers clinical care, biomedical research, and medical education, pioneering therapies including CAR T cell therapy, mRNA vaccines, and gene therapy while serving approximately 2.5–3 million patients annually.

Ownership category

akta.pro rank

Product category

Academic Medical Center & Specialty Healthcare Services

NAICS

General Medical and Surgical Hospitals (62211), Offices of Physicians (62111)

SIC

Services-General Medical & Surgical Hospitals, Nec (8062), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Academic Medical Centers & Teaching Hospitals (University-Affiliated) (EDAHAGAA)

akta.pro secondary industries

Primary Care & General Medicine Virtual Care (HLALAAAA), Home Infusion Therapy Providers (HLAFAEAE), Specialty Pharmacy & Complex Therapy Management Platforms (HLACAKAG)

Keywords

• Academic medical center
• Hospital healthcare services
• Cancer treatment center
• Telehealth virtual care
• Medical research education

Headquarters

HQ city

Philadelphia

HQ country

United States

HQ region

North America

Offices7 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Patient Care Services: Penn Medicine generates revenue primarily through patient care services across its six hospitals, hundreds of outpatient clinics, Penn Medicine at Home, and Penn Medicine OnDemand telehealth. Services include primary care, specialty care, cancer care, cardiac care, neurology, orthopaedics, transplant, and more. Revenue is generated through insurance reimbursements, Medicare/Medicaid, and out-of-pocket payments.
2. Research Funding: Penn Medicine and the Perelman School of Medicine receive over $969 million in annual research funding from NIH, foundations, and industry sponsors. Funding supports clinical trials, basic science research, and translational medicine programs. Over 2,320 clinical research studies underway with 151,426 patients enrolled.
3. Philanthropy and Donations: Penn Medicine receives philanthropic gifts through multiple foundations including the Abramson Cancer Center, Chester County Hospital Foundation, Lancaster General Health Foundation, Princeton Medical Center Foundation, and Doylestown Health Foundation. Major gifts support research, facilities, and patient programs.
4. Specialty Pharmacy Services: Penn Medicine's expanded specialty pharmacy handles temperature-sensitive drugs including GLP-1 medications, with home delivery through the RefillExpress system reducing specialty drug delivery times from 14-21 days to three days.

Pricing tiers

Go-to-market motion3 records

Distribution channels7 records

Marketing channels8 records

Core offering

Penn Medicine operates as an academic medical center providing patient care services across seven hospitals and hundreds of outpatient clinics spanning 27 counties in Pennsylvania and New Jersey, including cancer care (Abramson Cancer Center), cardiac care, neurology, organ transplantation, primary care, women's health, and orthopaedics. The organization delivers these services alongside biomedical research (over $969 million in annual funding, 2,320 active clinical trials) and medical education through the Perelman School of Medicine, while pioneering proprietary therapies such as CAR T cell therapy, mRNA vaccine technology, gene therapy (Luxturna), and AI-enabled clinical tools.

Product overview

Penn Medicine is a comprehensive academic medical center offering a broad portfolio of clinical services, specialized treatment centers, and technology-enabled healthcare solutions. The core clinical offerings span cancer care (Abramson Cancer Center with CAR T cell therapy and Cytalux fluorescent imaging), cardiovascular services, neurology, orthopaedics, primary care, and women's health across six hospitals. Technology products include Penn Medicine OnDemand (24/7 virtual urgent care platform), Chart Hero (AI-powered EHR synthesis tool), AInsights (AI diagnostic imaging platform), CRISP (AI physician training system), and Hospital at Home program. Supporting infrastructure includes RefillExpress pharmacy automation, Thrive care coordination program, and the Basser Center for BRCA. Research is supported by the Institute for RNA Innovation (550+ members), Institute for Immunology and Immune Health, and Penn Center for Innovation. The organization serves 300,000+ cancer patients annually, has completed 7,700+ kidney transplants, and manages 2,320+ clinical research studies.

Differentiator

Problem solved

Functional benefit

Brands

• Abramson Cancer Center: Comprehensive cancer center designated by the National Cancer Institute since 1973, one of 7 such centers in the United States
• Penn Medicine OnDemand
• Penn Center for Innovation
• Basser Center for BRCA
• Penn Aorta Center
• Institute for Immunology and Immune Health
• Penn Transplant Institute
• Institute for RNA Innovation
• Penn Medicine at Home
• Penn Personalized Care
• Clyde F. Barker Penn Transplant House
• Colton Center for Autoimmunity at Penn

Products and services

• Penn Medicine Hospital Network (Six-Seven Hospital System) Comprehensive inpatient and outpatient hospital services across seven hospitals in Pennsylvania and New Jersey, including cancer care, cardiac care, neurology, orthopaedics, transplant, primary care, and women's health.
• Penn Medicine OnDemand (Virtual Urgent Care) 24/7 virtual urgent care platform providing round-the-clock access to healthcare providers via video consultation, allowing patients to connect without physician referral. Telemedicine visits average $96 vs $509 for in-person visits.
• Penn Medicine at Home Home health program including skilled nursing, rehabilitation therapies, home health aides, palliative and hospice services, and social workers. Includes growing advanced healthcare at home such as cancer care, infusion therapy, and post-surgical visits.
• Abramson Cancer Center NCI-designated Comprehensive Cancer Center providing cancer research, treatment, and education across all cancer types. Serves 300,000+ patients annually with locations throughout Pennsylvania and New Jersey. Provides CAR T therapy, proton therapy, surgery, chemotherapy, immunotherapy, and access to clinical trials.
• CAR T Cell Therapy (Tisagenlecleucel / Kymriah) Pioneering cancer immunotherapy that reprograms a patient's own immune cells to target cancer cells. Originally developed for blood cancers (lymphoma, leukemia, multiple myeloma); now being investigated for solid tumors and kidney transplant desensitization.
• Cytalux Fluorescent Imaging Agent First FDA-approved fluorescent imaging agent for ovarian cancer that enables surgeons to identify additional disease during surgery that would be missed by traditional methods. In Phase III trial, identified additional disease in 33% of patients.
• Penn Transplant Institute One of the largest organ transplant programs in the country, performing kidney, liver, heart, lung, and pancreas transplants, including pioneering CAR T cell desensitization for highly sensitized patients.
• Hospital at Home Program Program allowing patients to receive hospital-level acute care at home rather than in traditional hospital settings, reducing need for in-patient hospitalization while delivering equivalent care quality.
• Basser Center for BRCA First comprehensive center dedicated to research, treatment, and prevention of BRCA-related cancers. Home to the Basser Cancer Interception Institute advancing cancer prevention vaccine research across breast, prostate, and ovarian cancer types.
• Penn Medicine Specialty Pharmacy & RefillExpress Expanded specialty pharmacy handling temperature-sensitive drugs including GLP-1 medications, with home delivery via the homegrown RefillExpress system that reduces specialty drug delivery times from 14-21 days to three days. Includes robotic pill dispensing.
• Thrive Care Coordination Program Intensive 30-day care coordination initiative for Medicaid-insured patients transitioning from hospital to home. Shows 50% reduction in readmissions at 30, 60, and 90 days by integrating virtual nurse case management, social workers, home care nurses, and hospital providers.
• Clyde F. Barker Penn Transplant House Accommodation facility for organ transplant patients and their families at $60 per night, with a goal of ensuring no family is turned away due to financial hardship.
• Penn Medicine Specialty Care Centers (Penn Aorta Center, Penn Orthopaedics, etc.) Specialized centers for aortic disease, orthopaedics (official partner of Philadelphia Flyers, 76ers, and Philadelphia Union), neurology, women's health, transplant, and LGBTQ+ health.

Quantifiable outcome

• Telemedicine visits cost $96 on average vs $509 for in-person visits — five-fold cost difference. Patients starting with telemedicine also required fewer follow-up visits.
• +11 more outcomes

Named customers7 records

Segments12 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability13 records

Feature15 records

Partnerships

20 partnerships are on record, tiered major, core and minor.

• Medicare Payment Advisory Commission (MedPAC)majorOthers · 12 June 2026Amol Navathe, a professor at Penn Medicine, was appointed as the new chair of MedPAC, the independent congressional agency advising Congress on Medicare payment policy. Medicare covers more than 67 million people.
• NYU Langone HealthmajorStrategic or Co-development Partner · 3 June 2026NYU Langone Health co-led a Phase I clinical trial with Penn Medicine demonstrating that CAR T cell therapy can safely desensitize highly sensitized kidney failure patients, enabling previously incompatible kidney transplants. Three patients with near-100% antibody levels successfully received transplants following the therapy.
• Mass GeneralmajorStrategic or Co-development Partner · 3 June 2026Mass General co-led Phase I clinical trial with Penn Medicine testing CAR T cell therapy to desensitize highly sensitized kidney failure patients for transplantation. The therapy successfully enabled three patients with near-100% antibody levels to receive previously incompatible donor kidneys.
• K HealthcoreTechnology or Integration · 27 May 2026Multi-year collaboration announced May 27, 2026 to deploy K Health's suite of artificial intelligence clinical agents across Penn Medicine's EHR platforms, beginning with Penn Medicine OnDemand's virtual urgent care program before expanding to in-person primary care, cardiology, and dermatology clinics. The AI engine dynamically interviews patients and generates pre-populated draft charts directly within the provider's EHR. K Health has raised $384M in total venture financing. The organizations will also co-develop peer-reviewed clinical research on clinical AI automation.
• K HealthcoreTechnology or Integration · 27 May 2026Penn Medicine partnered with K Health to deploy enterprise-wide clinical AI infrastructure across its health system, initially starting with virtual urgent care before expanding into in-person clinics. The AI platform automates patient intake and documentation, reduces administrative burdens, and streamlines care coordination. Includes collaborative research initiatives to measure AI's impact on workflow efficiency, patient engagement, and care outcomes.
• BriaCell TherapeuticsminorStrategic or Co-development Partner · 13 May 2026BriaCell Therapeutics added Penn Medicine's Abramson Cancer Center as a clinical trial site for its ongoing pivotal Phase 3 breast cancer study (Bria-ABC), evaluating Bria-IMT in combination with immune checkpoint inhibitors for advanced metastatic breast cancer. The study has FDA Fast Track designation. Other sites include Indiana University Melvin and Bren Simon Comprehensive Cancer Center, University of Virginia Comprehensive Cancer Center, Baptist Health South Florida, and SCRI Oncology Partners.
• Children's Hospital of Philadelphia (CHOP)coreStrategic or Co-development Partner · 30 April 2026Penn Medicine and CHOP jointly announced the appointment of Dr. Eric M. Morrow as founding director of the Lurie Autism Institute, effective September 1, 2026. The institute was launched in 2025 with a $50 million gift from the Jeffrey Lurie Family Foundation and Nancy Lurie Marks Family Foundation — the largest single donation to a U.S. academic medical center focused on autism research across the lifespan.
• Children's Hospital of Philadelphia (CHOP)coreStrategic or Co-development Partner · 29 April 2026Penn Medicine and CHOP collaborated on the Lurie Autism Institute launch with Dr. Eric M. Morrow as founding director. The institute aims to accelerate discovery and improve care by integrating genomic science, artificial intelligence, and institutional collaboration. Supported by $50 million from Jeffrey Lurie Family Foundation and Nancy Lurie Marks Family Foundation.
• Children's Hospital of Philadelphia (CHOP)coreStrategic or Co-development Partner · 22 April 2026Researchers from Penn Medicine and Children's Hospital of Philadelphia awarded the $3 million Breakthrough Prize for developing gene therapy for Leber congenital amaurosis (inherited blindness). The breakthrough enabled over 140 clinical trials for retinal diseases including macular degeneration and diabetic retinopathy.
• Children's Hospital of Philadelphia (CHOP)coreStrategic or Co-development Partner · 18 April 2026Penn Medicine and CHOP researchers jointly awarded the 2025 Breakthrough Prize in Life Sciences for developing Luxturna, the first FDA-approved gene therapy for inherited blindness. Jean Bennett and Albert Maguire (Penn Medicine) and Katherine High (CHOP) were recognized for their nearly 40-year research effort. Spark Therapeutics, a CHOP spinout, manufactured and commercialized the therapy.
• Children's Hospital of Philadelphia (CHOP)coreStrategic or Co-development Partner · 1 April 2026Researchers from CHOP and Penn Medicine reported results supporting a customizable in vivo prime editing platform for treating infantile-onset urea cycle disorders. The two-part system combining lipid nanoparticles and adeno-associated virus achieved 30-40% correction rates in preclinical studies, exceeding the ~10% threshold needed for clinical benefit.
• CHOP (on CRISPR Personalized Therapy)coreStrategic or Co-development Partner · 23 March 2026CHOP and Penn Medicine collaborated on the world's first personalized CRISPR-based gene therapy for infant KJ with CPS1 deficiency. CHOP researchers joined the FDA in announcing a new 'plausible mechanism' framework to accelerate approvals for individualized rare disease therapies.
• U.S. Congress / Federal GovernmentcoreOthers · 19 February 2026Congress passed federal appropriations bill H.R. 7148 extending Medicare telehealth coverage and the Acute Hospital Care at Home waiver through 2030, preserving pandemic-era healthcare flexibilities. Penn Medicine called the bill 'welcome stability' for biomedical research and accelerated plans to launch its hospital-at-home program.
• Family Practice & Counseling Services NetworkminorStrategic or Co-development Partner · 12 February 2026Penn Medicine provided financial and operational support to help Family Practice & Counseling Services Network form a new FQHC entity after federal rules prohibited it from retaining FQHC status under for-profit parent Inperium Inc. Penn helped the nonprofit successfully reapplied for a $3.4 million federal health center grant for Southwest Philadelphia.
• Epic SystemsmajorTechnology or Integration · 31 December 2025Epic Systems partnered with Penn Medicine to develop a technology-driven outpatient clinic that enhances healthcare delivery through digital tools and innovative solutions. The initiative aims to improve efficiency, personalization, and communication within outpatient settings, with plans to optimize patient check-in and data sharing.
• AramarkcoreImplementation/ SI/ Consulting Partner · 18 October 2025Aramark signed a systemwide agreement to provide food and support services at Penn Medicine starting early 2026. The contract is Aramark's second-largest ever and its biggest in the U.S., covering patient and retail food, environmental services, and patient transportation across Penn Medicine's seven-hospital system from Lancaster County to central New Jersey. Penn Medicine CEO Kevin B. Mahoney called it Aramark's largest U.S. contract win ever.
• AramarkcoreImplementation/ SI/ Consulting Partner · 9 October 2025Penn Medicine selected Aramark for its systemwide contract covering food and other services. The deal is Aramark's second-largest ever and its biggest in the U.S., covering hospital operation support across several locations in the Penn Medicine network.
• Cost Plus DrugsminorStrategic or Co-development PartnerPenn Medicine partnered with Cost Plus Drugs to purchase top generics at discounted rates, enabling the specialty pharmacy to offer medications at reduced costs to patients.
• NovartismajorStrategic or Co-development PartnerPenn Medicine's strategic partnership with Novartis resulted in FDA-approved CAR T therapy Kymriah (tisagenlecleucel), the first FDA-approved cellular therapy for cancer. This exemplifies Penn's shift from traditional patenting toward collaborative innovation models in drug development.
• BioNTechmajorStrategic or Co-development PartnerPenn Medicine's partnership with BioNTech built on mRNA technologies developed by Drew Weissman and Katalin Kariko, leading to the BioNTech/Pfizer COVID-19 vaccine. This collaboration exemplifies Penn's collaborative innovation models in translational medicine.

Scale indicators20 records

Recent moves7 records

Direct peers

• NewYork-Presbyterian / Columbia: Ivy League-affiliated academic medical center with overlapping clinical and research footprint, similar patient populations in the Mid-Atlantic, and parallel graduate medical education programs.
• NYU Langone Health: Elite New York academic medical center co-leading Penn's CAR T kidney desensitization trial. Comparable scale, NCI cancer programs, heavy research funding, and similar clinical-trial infrastructure make it the closest regional peer.
• Mass General Brigham: Harvard-affiliated academic medical system co-leading the same CAR T desensitization work as Penn. Directly comparable as a top-tier research-driven AMC with NIH funding, complex specialty care, and translational research leadership.
• Johns Hopkins Medicine: Closest national peer as the prototypical research-intensive academic medical center. Competes with Penn for NIH funding, NCI Comprehensive Cancer Center status, and complex specialty referrals with similar depth in research and clinical care.
• Cleveland Clinic: National academic medical system with comparable brand, complex specialty care (particularly cardiology, paralleling Penn's top heart program), and growing reach across multiple geographies (Ohio, Florida, Nevada).
• UCSF Health: West Coast academic medical center with analogous structure: medical school plus hospital system, heavy NIH funding, NCI cancer center designation, and similar translational research and clinical-trial capacity.
• Stanford Health Care: Ivy-equivalent academic medical center whose Silicon Valley location and tech-forward strategy make it a peer on AI in healthcare and biomedical informatics - directly comparable to Penn's AInsights, Chart Hero, and K Health partnerships.
• Mount Sinai Health System: NYC-based academic health system with analogous biomedical research scale, NCI-designated cancer center, and strong AI-in-medicine initiatives; competes for talent, grants, and complex patient referrals in the Northeast corridor.
• Duke University Health System: Private university-aligned academic medical system of comparable scale, with strong translational research programs, NCI cancer center, and outreach across the Carolinas that mirrors Penn's regional hub-and-spoke strategy in the Mid-Atlantic.
• UPMC (University of Pittsburgh Medical Center): Large Pennsylvania-based academic medical system with similar scale (~40,000+ employees, multi-billion enterprise value), extensive regional hospital network, and major research enterprise. Geographic overlap makes it a particularly close peer.

Market position

Strengths5 records

Weaknesses5 records

Key risks7 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/pennmedicine
• Xx.com/PennMedicine
• Facebookfacebook.com/pennmed
• LinkedInlinkedin.com/company/university-of-pennsylvania-health-system

Revenue estimate

Valuation estimate

Number of profiles

Profiles21 records

Subsidiaries7 records

Funding overview

Funding rounds7 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments6 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Penn Medicine